Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Heart Failure With Preserved Ejection Fraction

(2014) Kavita Sharma et al.   CIRCULATION RESEARCH

Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview

(2014) P.R.A. Heckman et al.   CURRENT PHARMACEUTICAL DESIGN

Advances in targeting cyclic nucleotide phosphodiesterases

(2014) Donald H. Maurice et al.   NATURE REVIEWS DRUG DISCOVERY

Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy

(2014) K. Seo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

(2013) Margaret M. Redfield et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β

(2013) Jonathan A. Kirk et al.   JOURNAL OF CLINICAL INVESTIGATION

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

(2013) Stephen J. Greene et al.   Journal of the American Heart Association

Nitric Oxide Synthases in Heart Failure

(2012) Ricardo Carnicer et al.   ANTIOXIDANTS & REDOX SIGNALING

Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction

(2012) Loek van Heerebeek et al.   CIRCULATION

A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo

(2012) Jennifer Davis et al.   DEVELOPMENTAL CELL

Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders

(2012) Patrick R. Verhoest et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection

(2012) Rakesh C. Kukreja et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Designer natriuretic peptides: a vision for the future of heart failure therapeutics

(2011) Rosita Zakeri et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes

(2011) Alessandra Stangherlin et al.   CIRCULATION RESEARCH

Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart

(2010) Hideyuki Kinoshita et al.   CIRCULATION RESEARCH

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation

(2009) Norimichi Koitabashi et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart

(2008) Bin Zhou et al.   NATURE